Dr. Gonzalo Hidalgo, a Neurologist at Reliant Specialty Infusions, said he believes his clinic is the first in Louisiana to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lillyand Co. (LLY), American ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...

Eli Lilly’s stock has hit a 52-week low at $697.35, nosediving over 10% this past week, which has investors holding their ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

That's why Veeva Systems should remain a leader in its niche and deliver excellent returns over the long run. It's a top stock to buy and hold for the next two decades.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...